Searchable abstracts of presentations at key conferences in endocrinology

ea0081p532 | Adrenal and Cardiovascular Endocrinology | ECE2022

Covid-19 in patients with hypocortisolism: clinical syndrome, disease duration and glucocorticoid replacement therapy

Simeoli Chiara , Schettino Serafina , La Rocca Angelica , Di Paola Nicola , Massimo Crescenzo Erminio , Ciardella Francesco , Mazzarella Alessandro , Pivonello Claudia , Colao Annamaria , Pivonello Rosario

Coronavirus disease caused by SARS-CoV-2 virus (Covid-19) is associated with a variable clinical syndrome, ranging from a mild-moderate to a severe disease, progressing towards acute respiratory distress syndrome. Hypocortisolism is associated with a depletion of innate immunity and disruption of immune response, which could contribute to an increased risk of infection and development of a severe disease. Glucocorticoid (GC) replacement therapy(GCRT), especially if administere...

ea0090p145 | Pituitary and Neuroendocrinology | ECE2023

Somatostatin receptor type 2 (SSTR2) expression regulation by miR-375 in a murine pituitary corticotroph tumor cell model

Pivonello Claudia , Patalano Roberta , Monto Tatiana , Negri Mariarosaria , Amatrudo Feliciana , Paola Provvisiero Donatella , Simeoli Chiara , Paola Nicola , Larocca Angelica , Massimo Crescenzo Erminio , Colao Annamaria , Pivonello Rosario

Cushing’s disease (CD), caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor, is the most common form of hypercortisolism. Pituitary surgery is the first-line treatment of CD and medical treatment is an alternative second-line approach to control cortisol excess. Long-term exposure to glucocorticoids (GC) downregulates the expression of somatostatin receptor type 2 (SSTR2) but not type 5 (SSTR5) in human and mouse ACTH-secreting tumor cell cultures; t...